InvestorsHub Logo
Followers 72
Posts 13186
Boards Moderated 0
Alias Born 06/03/2015

Re: georgesk post# 431720

Tuesday, 09/19/2023 10:25:19 PM

Tuesday, September 19, 2023 10:25:19 PM

Post# of 473770
Not true...

we're going the AA route because a full approval is pretty much impossible without hitting it.


The last PR stated that one co-primary endpoint, with p < .025, and a secondary endpoint with same, is acceptable for the FDA to grant approval. You don't think Jin knows this?

Anavex is introducing the key biomarkers to cover the AA base, if the FDA would prefer that route.

The company is playing it very well.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News